(VIANEWS) – Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) slid by a staggering 18.67% to kr0.37 at 11:24 EST on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI is dropping 0.29% to kr1,215.57, after three successive sessions in a row of losses. This seems, so far, a somewhat down trend exchanging session today.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-4.14.
Volume
Today’s last reported volume for BERGENBIO is 14123926 which is 1039.56% above its average volume of 1239420.
Volatility
BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.97%, a negative 4.67%, and a positive 7.65%.
BERGENBIO’s highest amplitude of average volatility was 51.69% (last week), 18.97% (last month), and 7.65% (last quarter).
More news about BERGENBIO (BGBIO.OL).
